Drugs / SPH3348
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05088070 | Jul 2020 → Jul 2023 | cancer | Shanghai Pharmaceuticals Holding Co., Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT06652997 Comparator | Jul → Aug 2022 | — | West China Second University Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPH 3348 | “Clinical Study of SPH3348 Tablets, a C-Met Inhibitor, in Patients with Advanced Solid Tumors” NCT05088070 ↗ |
| Action | Inhibit | “a C-Met inhibitor” NCT05088070 ↗ |
| Route | Oral | “will be orally administered once a day” NCT05088070 ↗ |
| Target | MET | “a C-Met inhibitor” NCT05088070 ↗ |